Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508338 · ClinicalTrials.gov registry record · NA
The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes
A NA study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01508338 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 44 participants.
The verdict
NCT01508338, a NA study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to * determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle hypertrophy, body composition, strength, force, velocity, and peak power during loaded and unloaded vertical jumps. Additionally, the study will determine if either supplementation protocol prevents the typical decay seen in performance following an overreaching cycle performed in the 9th and 10th weeks of the study. Finally, the study will elucidate the mechanisms of action of supplementation on protein breakdown by analyzing serum indices of muscle damage (CK, LDH) and anabolic status (Testosterone:Cortisol ratio) as well as a urinary indicator of protein breakdown (3-methylhistidine). We hypothesize that under these conditions that the supplementation protocols will augment skeletal muscle hypertrophy, strength, and power and that HMB will blunt increases in serum indices of muscle damage, and urinary indices of protein breakdown.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT ATP
- DIETARY_SUPPLEMENT HMB
- DIETARY_SUPPLEMENT Peak ATP and HMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508338
The ClinicalTrials.gov registry entry for NCT01508338 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01508338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508338 about?
NCT01508338 is a clinical study titled "The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes". The purpose of this study is to * determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle hypertrophy, body composition, strength, force, velocity, and peak power durin...
What is the current status of trial NCT01508338?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2012-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01508338?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), ATP (DIETARY_SUPPLEMENT), HMB (DIETARY_SUPPLEMENT), Peak ATP and HMB (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01508338?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.